Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells

Cancer Genetics and Cytogenetics

Volumn 199, Issue 2, 2010, Pages 89-95

  Larsson, Nina ^a   Billström, Rolf ^b   Lilljebjörn, Henrik ^a   Lassen, Carin ^a   Richter, Johan ^a   Ekblom, Marja ^a   Fioretos, Thoas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Hematology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENES, RAS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MIDDLE AGED; MONOSOMY; MUTATION; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RAS PROTEINS; THIAZOLES;

EID: 77952772669     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.02.005     Document Type: Article

References (33)

1. Fioretos T., Johansson B. Chronic myeloid leukemia. Cancer cytogenetics 2009, 179-207. Wiley-Blackwell, New York. 3rd ed. S. Heim, F. Mitelman (Eds.).
2. Quintás-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
3. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
4. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., Goldman J.M., Muller M.C., Radich J.P., Rudoltz M., Mone M., Gathmann I., Hughes T.P., Larson R.A. IRIS investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
5. Besalduch J., Guti Rrez A., Parody R., Bernu S.T. Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloide leukemia treated with imatinib (STI571). Haematologica 2003, 88. ELT03.
6. Abruzzese E., Gozzetti A., Galimberti S., Trawinska M.M., Caravita T., Siniscalchi A., Cervetti G., Mauriello A., Coletta A.M., De Fabritiis P. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007, 109:2466-2472.
7. Athanasiadou A., Lalayanni C., Papaioannou G., Gaitatzi M., Fassas A., Anagnostopoulos A. Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib. Leuk Lymphoma 2008, 49:1012-1013.
8. Bacher U., Hochhaus A., Berger U., Hiddemann W., Hehlmann R., Haferlach T., Schoch C. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005, 19:460-463.
9. - cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101:1941-1949.
10. Deininger M.W., Cortes J., Paquette R., Park B., Hochhaus A., Baccarani M., Stone R., Fischer T., Kantarjian H., Niederwieser D., Gambacorti-Passerini C., So C., Gathmann I., Goldman J.M., Smith D., Druker B.J., Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007, 110:1509-1519.
11. Espinet B., Oliveira A.C., Boqué C., Domingo A., Alonso E., Solé F. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica 2005, 90:556-558.
12. Jabbour E., Kantarjian H.M., Abruzzo L.V., O'Brien S., Garcia-Manero G., Verstovsek S., Shan J., Rios M.B., Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007, 110:2991-2995.
13. Kovitz C., Kantarjian H., Garcia-Manero G., Abruzzo L.V., Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006, 108:2811-2813.
14. Lin Y., Bruyère H., Horsman D.E., Pantzar T., Barnett M.J., Hogge D.E., Nevill T.J., Nantel S.H., Sutherland H.J., Toze C.L., Shepherd J.D., Lavoie J.C., Song K.W., Smith C.A., Forrest D.L. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 2006, 170:16-23.
15. Medina J., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Giles F., Rios M.B., Hayes K., Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003, 98:1905-1911.
16. Navarro J.T., Feliu E., Grau J., Espinet B., Colomer D., Ribera J.M., Oriol A., Granada I., Juncà J., Millá F. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol 2007, 82:849-851.
17. O'Dwyer M.E., Gatter K.M., Loriaux M., Druker B.J., Olson S.B., Magenis R.E., Lawce H., Mauro M.J., Maziarz R.T., Braziel R.M. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003, 17:481-487.
18. O'Shea D., Crotty G., Carroll P., Conneally E., McCann S., Neat M.J. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?. Br J Haematol 2004, 127:367-369.
19. Perel J.M., McCarthy C., Walker O., Irving I., Williams B., Kennedy G.A. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2005, 90. Suppl:ECR25.
20. Terre C., Eclache V., Rousselot P., Imbert M., Charrin C., Gervais C., Mozziconacci M.J., Maarek O., Mossafa H., Auger N., Dastugue N., Talmant P., Van den Akker J., Leonard C., N'Guyen Khac F., Mugneret F., Viguie F., Lafage-Pochitaloff M., Bastie J.N., Roux G.L., Nicolini F., Maloisel F., Vey N., Laurent G., Recher C., Vigier M., Yacouben Y., Giraudier S., Vernant J.P., Salles B., Roussi J., Castaigne S., Leymarie V., Flandrin G., Lessard M. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004, 18:1340-1346.
21. Zeidan A., Kakati S., Anderson B., Barcos M., Wetzler M. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genet Cytogenet 2007, 176:169-171.
22. ISCN 2009: an international system for human cytogenetic nomenclature 2009, S. Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
23. Agerstam H., Lilljebjörn H., Lassen C., Swedin A., Richter J., Vandenberghe P., Johansson B., Fioretos T. Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2007, 46:635-643.
24. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cavé H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia; a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
25. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
26. Fabarius A., Haferlach C., Müller M.C., Erben P., Lahaye T., Giehl M., Frank O., Seifarth W., Hehlmann R., Hochhaus A. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007, 92:834-837.
27. Cortes J.E., Talpaz M., Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996, 100:555-570.
28. Wang J.Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-5650.
29. Pitini V., Arrigo C., Sauta M.G., Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res 2009, 33:e143-e144.
30. Koike K., Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008, 141:567-575.
31. Flotho C., Steinemann D., Mullighan C.G., Neale G., Mayer K., Kratz C.P., Schlegelberger B., Downing J.R., Niemeyer C.M. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 2007, 26:5816-5821.
32. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., Faderl S., Bueso-Ramos C., Ravandi F., Estrov Z., Ferrajoli A., Wierda W., Shan J., Davis J., Giles F., Saba H.I., Issa J.P. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
33. Raj K., John A., Ho A., Chronis C., Khan S., Samuel J., Pomplun S., Thomas N.S., Mufti G.J. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21:1937-1944.